Skin Study

RCS-01: Sun-damaged and Aging Skin

In 2017, RepliCel completed a phase 1 human clinical trial of RCS-01 in patients with aging or sun-damaged skin. The study proved the product’s safety and provided very promising indications of the product’s potential efficacy in terms of impacting what we call ‘biomarkers’ in the layer under the skin which keeps it looking young and healthy.

We are currently working with our dermatology advisors to finalize the design of a phase 2 clinical study to evaluate the product’s ability to rejuvenate skin by countering the impact of aging and sun-damage (most notably, fine wrinkles).

The Phase 1 clinical trial investigating the injection of RCS-01 related to aging and UV-damaged skin demonstrated the product's safety and showed promising signals of the product's potential to rejuvenate the skin's youthful appearance by significantly impacting the biomarkers and levels of type 1 collagen, elastin and other critical extracellular dermal matrix components found in youthful skin.

Peer-reviewed Papers

RCS-01 for Aging and Sun-damage Skin

Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study